AcelRx jumps, Seeking Alpha contributor predicts buyout

|About: AcelRx Pharmaceuticals, Inc. (ACRX)|By:, SA News Editor

Shares of AcelRx (ACRX +9.6%) move sharply higher on heavy volume.

Perhaps helping the cause is an article from SA contributor Stock Matusow who points to a Sufentanil Nanotab NDA as a near-term catalyst.

Matusow also likes the company's cash position and isn't shy about the possibility of a takeout: "Based on the rumors we have heard, and comparing these rumors to the past performance of BOD members, we believe the company will be acquired within six months."